Welcome to our dedicated page for Modular Med news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Med stock.
Modular Medical Inc (NASDAQ: MODD) delivers innovative insulin pump technology designed to transform diabetes care. This news hub provides investors and healthcare professionals with essential updates on the company's progress in medical device development, regulatory milestones, and strategic partnerships.
Access timely information about MODD's patented diabetes management solutions, including FDA clearances, manufacturing expansions, and clinical advancements. Our curated news collection helps stakeholders track developments in user-friendly insulin delivery systems and the company's mission to expand access to affordable diabetes technology.
Key updates include product innovation timelines, regulatory submissions, intellectual property developments, and partnership announcements. Bookmark this page for consolidated access to MODD's latest achievements in medical device engineering and diabetes care solutions.
Modular Medical Inc. (NASDAQ:MODD) has announced CEO Jeb Besser's participation in two upcoming investor conferences. The H.C. Wainwright 24th Annual Global Investment Conference will be held from September 12-14, 2022, in New York, with Mr. Besser's presentation available on September 12 at 7:00 a.m. ET. Additionally, he will engage in one-on-one meetings at the Lake Street Capital Markets 6th Annual Best Ideas Growth Conference on September 14. Modular Medical aims to innovate affordable insulin pump technology, making diabetes care accessible to a broader audience.
Modular Medical (NASDAQ:MODD) announced the appointment of Dr. Anne Peters to its Advisory Board, enhancing its focus on improving diabetes care in under-resourced communities. Dr. Peters, a leading diabetes clinician, will collaborate with Modular Medical's leadership as they finalize their FDA 510k submission. With over 200 publications and extensive research experience, Dr. Peters aims to leverage her expertise to enhance access to insulin delivery technology. The company is committed to achieving affordable and effective glycemic control for all diabetes patients.
Modular Medical, Inc. (NASDAQ:MODD) announced the appointment of Kevin Schmid as Chief Operating Officer, bringing over 40 years of experience in medical devices and drug delivery. Previously, Schmid served at Insulet Corporation, helping develop innovative drug delivery systems like the Omnipod. His expertise in high-volume manufacturing and operational leadership is expected to aid Modular Medical's transition to commercialization of its insulin delivery technology, aimed at improving affordability and access for diabetes management.
Modular Medical Inc. (NASDAQ:MODD) is set to present at the LD Micro Invitational XII Investor Conference on June 8, 2022, at 3:30 PM PT in Westlake Village, California. CEO Jeb Besser will hold one-on-one meetings with institutional investors and analysts throughout the event. Modular Medical aims to revolutionize insulin delivery with affordable, user-friendly insulin pump technology, improving access to glycemic control for individuals with diabetes. The company was founded by Paul DiPerna, known for his role in developing Tandem Diabetes' t:slim insulin pump.
Modular Medical, Inc. (NASDAQ:MODD) will present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 18, 2022, at 1:00 p.m. ET. CEO Jeb Besser will discuss the company’s innovative insulin delivery technology aimed at making insulin pumps more affordable and user-friendly. The event will include one-on-one meetings with investors, and interested parties can view the presentation live or as a replay. Modular Medical aims to revolutionize diabetes management with its patented technologies, enhancing access to effective glycemic control.
Modular Medical (NASDAQ:MODD) announced a registered direct offering of 449,438 shares at $4.45 each, and pre-funded warrants to purchase 1,348,314 additional shares at $4.44 each. A concurrent private placement will issue warrants for 1,438,202 shares at an exercise price of $6.60, with expected gross proceeds of $8 million. The Company plans to utilize the funds for operations, product development, and general corporate purposes. Closing is expected around May 5, 2022, pending customary conditions.
Modular Medical Inc. (NASDAQ: MODD) announced its presentation at Oppenheimer's 32nd Annual Healthcare Conference on March 15, 2022. CEO Jeb Besser will represent the company in a virtual session starting at 8:40 am Eastern Time. A webcast of the presentation will be accessible at modular-medical.com/events and archived for 30 days. Modular Medical aims to launch innovative insulin pump technology, improving ease of use and affordability for diabetes management.
Modular Medical has appointed James "Jeb" Besser as its new CEO, effective immediately. Besser, with 25 years of experience in life sciences and technology, previously served as managing member of Manchester Management LLC, the company’s largest shareholder. Lynn Vos, the outgoing CEO since August 2021, remains on the board and will assist in marketing strategies. The company also reaffirmed its timeline for the 510(k) submission of its next-generation MODD1 insulin pump to the FDA, expected in Q2 2022, aiming to improve access to insulin delivery technology.
Modular Medical, Inc. (NASDAQ:MODD) has priced its underwritten public offering of 2,500,000 units at $6.00 each, with expected gross proceeds of $15 million. Each unit comprises one share and one warrant. The proceeds will fund corporate purposes, sales infrastructure, R&D, production capabilities, and repayment of a promissory note. The company’s common stock is now approved for listing on the Nasdaq Capital Market starting February 10, 2022. The offering is set to close on February 14, 2022.
Modular Medical, Inc. (OTCQB:MODD) has expanded its Board of Directors by appointing Steven G. Felsher and Philip B. Sheibley as independent directors. CEO Lynn O'Connor Vos highlighted their extensive experience, which will be invaluable as the company aims to enhance insulin pump technology for better diabetes care, particularly for underserved communities. Felsher brings over 30 years of financial and management expertise, while Sheibley focuses on life sciences consulting, further strengthening the company's leadership as it prepares for product commercialization.
